Alysia Funk
Family · Bruceton Mills, WVNPI 1861742629
Payments from drug & device makers
Across 392 payments — averaging $17.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- AstraZeneca$764
- Lilly USA, LLC$510
- Otsuka America Pharmaceutical, Inc.$358
- Novo Nordisk$299
- Boehringer Ingelheim$291
- plus $3K from 34 others
What the payments were for
- Food & beverage$6,64299%
- Education$341%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 99 | $1,632 |
| AstraZeneca | 42 | $764 |
| Lilly USA, LLC | 31 | $510 |
| Otsuka America Pharmaceutical, Inc. | 22 | $358 |
| Novo Nordisk | 18 | $299 |
| Boehringer Ingelheim | 19 | $291 |
| Amgen | 17 | $281 |
| Pfizer | 15 | $252 |
| Sanofi-aventis U.S. LLC | 14 | $220 |
| Merck | 13 | $191 |
| Exact Sciences | 10 | $187 |
| Abbott | 8 | $164 |
| GSK | 10 | $157 |
| Novartis | 10 | $157 |
| Mylan Specialty L.p. | 6 | $144 |
| Bayer | 7 | $127 |
| Phathom Pharmaceuticals, Inc. | 6 | $112 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $98 |
| Avanir Pharmaceuticals, Inc. | 5 | $96 |
| Alkermes, Inc. | 3 | $83 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $71 |
| Biohaven Pharmaceuticals, Inc. | 3 | $66 |
| Eisai Inc. | 4 | $62 |
| Inspire Medical Systems, Inc. | 1 | $39 |
| Organon | 3 | $37 |
| GRT US Holding, Inc. | 1 | $32 |
| Edwards Lifesciences | 1 | $27 |
| E.r. Squibb & Sons, L.L.C. | 2 | $24 |
| Amarin Pharma, Inc. | 1 | $20 |
| Medtronic | 1 | $19 |
| Mayne Pharma Commercial LLC | 1 | $19 |
| Advanced Respiratory, Inc | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Insulet Corporation | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Lundbeck LLC | 1 | $15 |
| Shield Therapeutics Inc | 1 | $14 |
| Sanofi | 1 | $13 |
| Johnson & Johnson | 1 | $12 |
How this compares
$6,676 in reported general payments places this provider in the 95th percentile of 1,507 family providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 86 | $106,972 |
| TrulicityDulaglutide | 48 | $80,899 |
| EliquisApixaban | 47 | $71,114 |
| MounjaroTirzepatide | 42 | $46,384 |
| OzempicSemaglutide | 30 | $38,287 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $27,134 |
| JanuviaSitagliptin Phosphate | 27 | $20,681 |
| FarxigaDapagliflozin Propanediol | 11 | $14,886 |
| XareltoRivaroxaban | 11 | $13,186 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $10,012 |
| NamzaricMemantine Hcl/Donepezil Hcl | 12 | $6,813 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $5,869 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 26 | $5,068 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $4,986 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 98 | $3,444 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $510 | $127,28390 claims |
| Boehringer IngelheimJardiance | $291 | $106,97286 claims |
| PfizerEliquis | $252 | $71,11447 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix | $157 | $42,21468 claims |
| Novo NordiskOzempic | $299 | $38,28730 claims |
| MerckJanuvia | $191 | $20,68127 claims |
| AstraZenecaFarxiga | $764 | $14,88611 claims |
| Johnson & JohnsonXarelto | $12 | $13,18611 claims |
| AbbVieNamzaric, Synthroid | $1,632 | $7,86235 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,507 family providers in West Virginia.
Other family in Bruceton Mills
- Ashley ComerCharleston$213K
- Dana CruseParkersburg$109K
- Sarah KnightCharleston$99K
- Star RoeBarboursville$55K
- Angela SettleCharleston$51K
- Amber DuncanCross Lanes$44K
- Jennifer FieldsHuntington$32K
- Gina LatheyScott Depot$31K
- Jodi BillerScott Depot$29K
- Misty BareboHuntington$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.